Publications by authors named "Jim Cassidy"

Claim this Profile
T
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
Timothy Iveson, Mark P Saunders, Caroline Kelly, Rachel S Kerr, Jim Cassidy

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.
Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, Rachel S Kerr, Mark P Saunders, Jim Cassidy

JAMA Surg· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Jim Cassidy

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Jim Cassidy

Health Technol Assess· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.
Katy L Simonsen, Paula M Fracasso, Steven H Bernstein, Megan Wind-Rotolo, Manish Gupta, Jim Cassidy

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, Timothy Iveson, Rachel S Kerr, Jim Cassidy

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, Jim Cassidy, Niels Henrik Hollander

Lancet Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.
Natividad Gomez-Roman, Neha Mohan Sahasrabudhe, Fiona McGregor, Anthony J Chalmers, Jim Cassidy

Oncotarget· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Ann Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Tamas Hickish, Jim Cassidy, David Propper, Ian Chau, Stephen Falk

Eur J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XELOX in colorectal cancer: a convenient option for the future?
Colin R Lindsay, Jim Cassidy

Expert Rev Gastroenterol Hepatol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
David Miles, Nadia Harbeck, Bernard Escudier, Herbert Hurwitz, Leonard Saltz, Jim Cassidy

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The third symptom management research trial in oncology (SMaRT oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (depression care for people with lung cancer) to usual care, compared to usual care alone in patients with lung cancer.
Jane Walker, Jim Cassidy, Michael Sharpe,

Trials· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Colin R Lindsay, Iain Rj MacPherson, Jim Cassidy

Future Oncol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients.
Jane Walker, Jim Cassidy, Michael Sharpe,

Trials· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Hendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, Eduardo Diaz-Rubio, Jean-Yves Douillard

J Clin Oncol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corporate crisis management managing a major crisis in a chemical facility.
Steve Marwitz, Neil Maxson, Bill Koch, Todd Aukerman, Jim Cassidy

J Hazard Mater· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
Janet S Graham, Ruth Plummer, Candice McCoy, Kristin Kowal, Herbert Wiesinger, Jim Cassidy

Eur J Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radio-chemotherapy in rectal cancer.
Jim Cassidy

Eur J Cancer· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab for the treatment of patients with colorectal cancer.
Jim Cassidy

Nat Clin Pract Oncol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Daniel G Haller, Jim Cassidy, Stephen J Clarke, David Cunningham, Eric Van Cutsem

J Clin Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Jim Cassidy, Hans-Joachim Schmoll, Eric Van Cutsem

J Clin Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Hilary Glen, Jim Cassidy

Expert Rev Anticancer Ther· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Jim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Jim Cassidy

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis